Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EXACT Therapeutics AS ( (DE:56F) ) has issued an update.
EXACT Therapeutics has commenced dosing in its Phase 2 ENACT trial, which explores the safety and efficacy of Acoustic Cluster Therapy (ACT®) combined with standard chemotherapy for pancreatic cancer patients. This trial marks a significant step in addressing the urgent need for new treatments in pancreatic cancer, a disease with high mortality and limited options, and follows promising results from a Phase 1 trial targeting liver metastases.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company specializing in targeted drug delivery using ultrasound and microbubbles. Their primary focus is on oncology, with applications extending to other conditions such as brain diseases. The company is publicly traded on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 23,444
Current Market Cap: NOK165.7M
For a thorough assessment of 56F stock, go to TipRanks’ Stock Analysis page.